磷霉素对含 blaKPC 肺炎克雷伯菌分离株的体外活性研究，包括那些对替加环素和/或多粘菌素不敏感的分离株。
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.
机构信息
Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
出版信息
Antimicrob Agents Chemother. 2010 Jan;54(1):526-9. doi: 10.1128/AAC.01235-09. Epub 2009 Nov 9.
Abstract
In vitro activity of fosfomycin was evaluated against 68 bla(KPC)-possessing Klebsiella pneumoniae (KpKPC) isolates, including 23 tigecycline- and/or colistin-nonsusceptible strains. By agar dilution, 93% of the overall KpKPC were susceptible (MIC(50/90) of 16/64 microg/ml, respectively). The subgroup of 23 tigecycline- and/or colistin-nonsusceptible strains showed susceptibility rates of 87% (MIC(50/90) of 32/128 microg/ml, respectively). Notably, 5 out of 6 extremely drug-resistant (tigecycline and colistin nonsusceptible) KpKPC were susceptible to fosfomycin. Compared to agar dilution, disk diffusion was more accurate than Etest.
摘要
体外研究评估了磷霉素对 68 株携带 bla(KPC)的肺炎克雷伯菌（KpKPC）的活性，包括 23 株对替加环素和/或黏菌素不敏感的菌株。琼脂稀释法的结果显示，总体上 93%的 KpKPC 对磷霉素敏感（MIC50/90 分别为 16/64μg/ml）。23 株对替加环素和/或黏菌素不敏感的菌株的敏感率为 87%（MIC50/90 分别为 32/128μg/ml）。值得注意的是，6 株极度耐药（对替加环素和黏菌素不敏感）的 KpKPC 中有 5 株对磷霉素敏感。与琼脂稀释法相比，纸片扩散法比 Etest 更准确。
相似文献
1
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.
Antimicrob Agents Chemother. 2010 Jan;54(1):526-9. doi: 10.1128/AAC.01235-09. Epub 2009 Nov 9.
2
In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
Diagn Microbiol Infect Dis. 2013 Jul;76(3):335-8. doi: 10.1016/j.diagmicrobio.2013.04.004. Epub 2013 May 29.
3
Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
J Microbiol Immunol Infect. 2017 Dec;50(6):931-939. doi: 10.1016/j.jmii.2016.12.008. Epub 2017 Jul 6.
4
In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Int J Antimicrob Agents. 2015 Dec;46(6):616-21. doi: 10.1016/j.ijantimicag.2015.07.021. Epub 2015 Sep 9.
5
The role of colonization pressure in the dissemination of colistin or tigecycline resistant KPC-producing Klebsiella pneumoniae in critically ill patients.
Infection. 2014 Oct;42(5):883-90. doi: 10.1007/s15010-014-0653-x. Epub 2014 Jul 10.
6
Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
Int J Antimicrob Agents. 2011 Mar;37(3):244-7. doi: 10.1016/j.ijantimicag.2010.10.031. Epub 2011 Jan 13.
7
Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
Antimicrob Agents Chemother. 2014;58(3):1757-62. doi: 10.1128/AAC.00741-13. Epub 2014 Jan 6.
8
Evaluation of in vitro methods for testing tigecycline combinations against carbapenemase-producing Klebsiella pneumoniae isolates.
J Glob Antimicrob Resist. 2020 Mar;20:98-104. doi: 10.1016/j.jgar.2019.07.028. Epub 2019 Aug 6.
9
Discrepancies in fosfomycin susceptibility testing of KPC-producing Klebsiella pneumoniae with various commercial methods.
Diagn Microbiol Infect Dis. 2019 Jan;93(1):74-76. doi: 10.1016/j.diagmicrobio.2018.07.014. Epub 2018 Jul 31.
10
In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.
J Antimicrob Chemother. 2014 Jul;69(7):1856-65. doi: 10.1093/jac/dku065. Epub 2014 Mar 19.
引用本文的文献
1
Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant .
Microbiol Spectr. 2024 Jun 4;12(6):e0010724. doi: 10.1128/spectrum.00107-24. Epub 2024 May 7.
2
[UhpT mutation along with the presence of genes in the genome probably contributes to inherent fosfomycin resistance of ].
Nan Fang Yi Ke Da Xue Xue Bao. 2023 Jul 20;43(7):1110-1115. doi: 10.12122/j.issn.1673-4254.2023.07.07.
3
Detection of Carbapenem-resistance in CRE by Comparative Assessment of RAPIDEC CARBA NP and Xpert™Carba-R Assay.
Infect Drug Resist. 2023 Feb 22;16:1123-1131. doi: 10.2147/IDR.S393739. eCollection 2023.
4
Transporter Genes and fosA Associated With Fosfomycin Resistance in Carbapenem-Resistant .
Front Microbiol. 2022 Jan 31;13:816806. doi: 10.3389/fmicb.2022.816806. eCollection 2022.
5
The Genomic Characterization of KPC-Producing from the ICU of a Teaching Hospital in Shanghai, China.
Infect Drug Resist. 2022 Jan 11;15:69-81. doi: 10.2147/IDR.S343673. eCollection 2022.
6
Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers.
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01375-20.
7
Fosfomycin, Applying Known Methods and Remedies to A New Era.
Diseases. 2020 Aug 7;8(3):31. doi: 10.3390/diseases8030031.
8
Multiple-Dose Oral Fosfomycin for Treatment of Complicated Urinary Tract Infections in the Outpatient Setting.
Open Forum Infect Dis. 2020 Jan 29;7(2):ofaa034. doi: 10.1093/ofid/ofaa034. eCollection 2020 Feb.
9
Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia.
J Clin Med. 2020 Jan 19;9(1):275. doi: 10.3390/jcm9010275.
10
The Role of in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates.
J Clin Microbiol. 2019 Sep 24;57(10). doi: 10.1128/JCM.00634-19. Print 2019 Oct.
本文引用的文献
1
ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
Antimicrob Agents Chemother. 2009 Oct;53(10):4504-7. doi: 10.1128/AAC.00556-09.
2
Susceptibility of urinary tract bacteria to fosfomycin.
Antimicrob Agents Chemother. 2009 Oct;53(10):4508-10. doi: 10.1128/AAC.00721-09. Epub 2009 Aug 17.
3
High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection.
J Antimicrob Chemother. 2009 Sep;64(3):574-8. doi: 10.1093/jac/dkp230. Epub 2009 Jul 3.
4
Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model.
J Antimicrob Chemother. 2009 Sep;64(3):563-6. doi: 10.1093/jac/dkp224. Epub 2009 Jun 26.
5
In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases.
Antimicrob Agents Chemother. 2009 Aug;53(8):3599-601. doi: 10.1128/AAC.00641-09. Epub 2009 Jun 15.
6
Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature.
Clin Infect Dis. 2009 Jul 15;49(2):271-4. doi: 10.1086/600042.
7
Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece.
J Antimicrob Chemother. 2009 Aug;64(2):348-52. doi: 10.1093/jac/dkp207. Epub 2009 Jun 13.
8
Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258.
Antimicrob Agents Chemother. 2009 Aug;53(8):3365-70. doi: 10.1128/AAC.00126-09. Epub 2009 Jun 8.
9
The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.
Int J Antimicrob Agents. 2009 Nov;34(5):407-13. doi: 10.1016/j.ijantimicag.2009.04.012. Epub 2009 Jun 7.
10
Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.
Int J Antimicrob Agents. 2009 Aug;34(2):111-20. doi: 10.1016/j.ijantimicag.2009.03.009. Epub 2009 Apr 28.
Zotero 插件